Risk Factors for the Loss of Lean Body Mass After Gastrectomy for Gastric Cancer.

about

Clinical Outcomes of Gastric Cancer Patients Who Underwent Proximal or Total Gastrectomy: A Propensity Score-Matched Analysis.Multidisciplinary therapy for scirrhous gastric cancer: a retrospective analysis and proposal of new treatment strategy

P2860

Q47618107-696253F7-7620-4A6C-94DF-E9F26A25B2E7 Q57070174-12D0D0B4-9B21-4CEF-BF9A-C83B02EBC553

P2860

Risk Factors for the Loss of Lean Body Mass After Gastrectomy for Gastric Cancer.

Item

http://www.wikidata.org/entity/Q38921403

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Risk Factors for the Loss of Lean Body Mass After Gastrectomy for Gastric Cancer.

@en

type

Item

label

Risk Factors for the Loss of Lean Body Mass After Gastrectomy for Gastric Cancer.

@en

prefLabel

Risk Factors for the Loss of Lean Body Mass After Gastrectomy for Gastric Cancer.

@en

P1476

Risk Factors for the Loss of Lean Body Mass After Gastrectomy for Gastric Cancer.

@en

P2093

Haruhiko Cho

http://www.w3.org/2001/XMLSchema#string

Hirohito Fujikawa

http://www.w3.org/2001/XMLSchema#string

Kazuhito Tsuchida

http://www.w3.org/2001/XMLSchema#string

Kazuki Kano

http://www.w3.org/2001/XMLSchema#string

Kenki Segami

http://www.w3.org/2001/XMLSchema#string

Munetaka Masuda

http://www.w3.org/2001/XMLSchema#string

Norio Yukawa

http://www.w3.org/2001/XMLSchema#string

Taiichi Kawabe

http://www.w3.org/2001/XMLSchema#string

Takaki Yoshikawa

http://www.w3.org/2001/XMLSchema#string

Takanobu Yamada

http://www.w3.org/2001/XMLSchema#string

P2860

Global cancer statistics, 2002

Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine

Dose-response effect of adjuvant chemotherapy in breast cancer

Ghrelin treatment reverses the reduction in weight gain and body fat in gastrectomised mice

Ghrelin stimulates gastric acid secretion and motility in rats.

Ghrelin, an endogenous growth hormone secretagogue, is a novel orexigenic peptide that antagonizes leptin action through the activation of hypothalamic neuropeptide Y/Y1 receptor pathway.

Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial.

Starvation in man.

Ghrelin induces abdominal obesity via GHS-R-dependent lipid retention

Sepsis is associated with increased mRNAs of the ubiquitin-proteasome proteolytic pathway in human skeletal muscle

P2888

s10434-015-5080-4

P304

1963-1970

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1245/S10434-015-5080-4

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2016-01-13T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1033632514

http://www.w3.org/2001/XMLSchema#string

P698

26762272

http://www.w3.org/2001/XMLSchema#string

P921

gastrectomy

Risk Factors for the Loss of Lean Body Mass After Gastrectomy for Gastric Cancer.

about

P2860

P2860

Risk Factors for the Loss of Lean Body Mass After Gastrectomy for Gastric Cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698

P921

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P433

P478

P577

P6179

P698

P921